Clinical trials: Ticagrelor
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Acute Myocardial Infarction
Ticagrelor for PCI Post Thrombolysis
Ticagrelor is a first line therapy along with aspirin for patients undergoing primary PCI for STEMI. However, many patients are still treated with fibrinolytic therapy and the safety and efficacy of Ticagrelor has not been…
- Trial name
- SETFAST (NCT01930591)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 5 sites in Canada
- Volunteers
- 140 people
- Sponsor
- Unity Health Toronto
Aortic Valve Stenosis
Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)
Transcatheter Aortic Valve Implantation (TAVI) is now the method of choice to treat aortic stenosis in old and frail patients. Antiplatelet therapy must be associated for the procedure and during few weeks after implantation in…
- Trial name
- TICTAVI (NCT02817789)
- Testing
- Ticagrelor alone, Combination lysine acetylsalicylate - clopidogrel
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Acute Coronary Syndrome
RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy
This NIS is a multi-centre, observational, descriptive, cross-sectional study including all consecutive patients with Acute Coronary Syndrome (ACS) and a single-arm, prospective, longitudinal cohort study which will include…
- Trial name
- STREAM (NCT02288260)
- Where
- 15 sites in Russia
- Volunteers
- 5,470 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS).
- Trial name
- NCT02889549
- Testing
- ticagrelor, clopidogrel
- Where
- 2 sites in United States, China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Healthy
Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers
The purpose of this study is to assess the pharmacokinetics of AZD6140 and its active metabolite, safety, tolerability of AZD6140 following single administration in healthy male Japanese volunteers.
- Trial name
- NCT01588626
- Testing
- AZD6140
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease
Ticagrelor vs Clopidogrel Effect on MFR in CAD Population
Ticagrelor is one of 3 anti-platelet medications used in patients with acute coronary syndrome (ACS) to prevent further clot formation and further ischemic damage to myocardial tissue.
- Trial name
- PATH (NCT01894789)
- Testing
- Ticagrelor, Clopidogrel
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Acute Coronary Syndrome
Antithrombotic Effects of Ticagrelor Versus Clopidogrel
The purpose of this study is to determine whether treatment with ticagrelor (plus aspirin and bivalirudin) is more effective than treatment with clopidogrel (plus aspirin and bivalirudin).
- Trial name
- NCT01642238
- Testing
- Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Juan J Badimon
Gout, Coronary Artery Disease
Uric Acid Study in Healthy Male Volunteers
This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.
- Trial name
- NCT00738842
- Testing
- AZD6140
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent
Background: The optimal duration of dual antiplatelet therapy in ACS patients treated with DES is still under debate. This is especially true for STEMI patients in the era of new anticoagulants and antiplatelet agents.
- Trial name
- REDUCE (NCT02118870)
- Testing
- Treatment 90 days DAPT, Treatment 360 days DAPT
- Volunteers
- 1,500 people
- Sponsor
- Diagram B.V.
Cerebrovascular Accident, Cerebrovascular Accident, Acute
Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke
Cerebrovascular disease is the main cause of death and severe long-term disability worldwide. Antiplatelet drugs are the main drugs for ischemic stroke and TIA.
- Trial name
- NCT04962451
- Testing
- ticagrelor + ASA
- Where
- China
- Volunteers
- 13,000 people
- Sponsor
- Peking University Third Hospital
Myocardial Ischemia
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease
The aim of this study is to assess the pleiotropic effects of ticagrelor that could represent possible mechanisms for its beneficial effects on cardiovascular mortality. We will test three different hypotheses: 1.
- Trial name
- TAPER-S (NCT02701140)
- Testing
- Coronary stenting, intracoronary ECG recording, Coronary Flow reserve
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Italo Porto
Coronary Artery Disease, Stable Angina
Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG
The primary objective of this study ist to test the hypothesis that ticagrelor is superior to Aspirin (ASA) fort he prevention of major cardio- and cerebrovascular events (MACCE) in patients undergoing artery bypass operation.
- Conditions
- Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- TiCAB (NCT01755520)
- Testing
- Ticagrelor, Aspirin
- Where
- 29 sites in Austria, Germany and 1 more
- Volunteers
- 1,893 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Peripheral Arterial Disease
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
This is a single center, prospective, randomized, unblinded, open-label, active controlled pilot study to evaluate the efficacy and safety of ticagrelor plus aspirin versus clopidogrel plus aspirin in patients with Rutherford…
- Trial name
- NCT02230527
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- The Cleveland Clinic
Healthy
The Antiplatelet and Immune Response Trial
Platelets are the main type of blood cell involved in the formation of blood clots that cause heart attacks. The investigators give antiplatelet drugs (aspirin, for example) to reduce the risk of another clot forming in the…
- Trial name
- NCT01846559
- Testing
- Endotoxin, Clopidogrel, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Assess the pharmacodynamic effect of ticagrelor vs. Clopidogrel in American Indian patients with stable coronary artery disease.
- Trial name
- NCT01706510
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rapid City Regional Hospital, Inc
STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction
The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction
300 STIMI patients with LV systolic dysfunction will be divided into two equal groups (Group I (Study arm, n=150); will receive dapagliflozin plus conventional therapy and group (II) Control arm (n=150); will receive conventional…
- Trial name
- NCT05045274
- Testing
- Dapagliflozin 10Mg Tab
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Assiut University
Arterial Thrombosis
Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus
Recombinant staphylokinase (r-SAK) is a third-generation thrombolytic agent produced by genetic engineering technology in 1985, which has better thrombolytic effect than streptokinase (SK) and urokinase (UK).
- Trial name
- NCT05978791
- Testing
- collection of venous blood or arterial blood
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Coronary Artery Disease
Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI
To determine the safety and efficacy of Ticagrelor versus Clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary…
- Trial name
- PL-PLATELET (NCT03078465)
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Sponsor
- Nanjing First Hospital, Nanjing Medical University